Highest-materiality recent filing
FibroBiologics closes $3M private placement; warrants could add $6M
Gross proceeds of $3.0M from sale of 4.08M shares/pre-funded warrants + warrants at $0.735/share.
FibroBiologics ups ATM offering to $7.5M; 71,830 shares sold to date
Increased maximum aggregate offering price under ATM facility to $7.5 million.
FibroBiologics regains full compliance with Nasdaq listing requirements; monitoring periods imposed
Nasdaq confirmed compliance with $2.5M stockholders' equity rule (Mar 9) and $1.00 bid price rule (Apr 17).
FibroBiologics closes $3M public offering of common stock and warrants at $1.32/unit
Offering of 2,272,728 shares (or pre-funded warrants) plus warrants, combined price $1.32/unit; net proceeds ~$2.5M after fees.
FibroBiologics stockholders approve reverse stock split and warrant issuances
Reverse stock split approved at ratio between 1:5 and 1:30, with board discretion; 53.6M votes for, 1.3M against.
FibroBiologics receives Nasdaq delisting notice for continued MVLS non-compliance
Nasdaq notified FibroBiologics on Feb 3, 2026 that continued failure to meet the $35M MVLS minimum adds a delisting basis.
Nasdaq notified delisting on Dec 30, 2025, after 180-day cure period ended Dec 29 without compliance.
FibroBiologics raises ~$1.7M in registered direct offering at $0.33/share with warrants
Sold 5,227,275 shares at $0.33/share; gross proceeds ~$1.7M; closing expected Dec 16, 2025.
FibroBiologics raises $1.5M in registered direct offering priced at $0.335/share
Sold 4,477,614 shares at $0.335/share; gross proceeds ~$1.5M before fees.
FibroBiologics raises ~$4M in registered direct offering paid in gold coins; redeems $3.4M note
Priced 3,540,000 shares and 8,570,203 pre-funded warrants at $0.3303/unit, gross proceeds ~$4M.
FibroBiologics receives Nasdaq MVLS deficiency notice; 180-day cure period to Feb 2026
Nasdaq notified FibroBiologics on Aug 4, 2025 that its MVLS fell below the $35M minimum for continued listing.
FibroBiologics amends 8-K to disclose up to 41.4M shares issuable under SEPA with YA II PN
Maximum shares convertible from $15M promissory notes: 36,945,812 shares at $0.406/share.
FibroBiologics converts $1.4M of notes, issues 2.15M shares at ~$0.65 avg price
On June 20-27 and July 15, 2025, YA II PN converted $1.4M of Second and Third Notes into 2,154,530 common shares.
FibroBiologics receives Nasdaq bid price deficiency notice; 180 days to cure
Nasdaq notified FibroBiologics on July 1, 2025 that common stock closing bid price was below $1.00 for 30 consecutive trading days.
Third $5M tranche of $15M pre-paid advance drawn; total $15M now under SEPA with YA II PN, Ltd.
FibroBiologics closes $5M second tranche of convertible note; grants CEO/CSO options
Second $5M tranche under SEPA with YA II PN (Yorkville) funded Dec 30, 2024; convertible note bears 0% interest (18% on default).
FibroBiologics secures up to $25M standby equity facility with Yorkville; first $5M funded
Yorkville advanced $5M initial tranche of $15M pre-paid convertible notes; two additional $5M tranches subject to conditions.
FibroBiologics issues 1.15M shares at $2.17, terminates GEM SPA and warrant
Sold 1,152,074 shares to GEM at $2.17/share for aggregate $2.5M.
FibroBiologics enters 5-year MSA with Charles River Labs for development and manufacturing services
Master Services Agreement with Charles River Laboratories effective September 19, 2024.
FibroBiologics pipeline update: CYWC628 pre-clinical data shows improved wound healing vs Grafix
CYWC628 multiple administration study: 69.3% wound area reduction at day 12 vs 47.13% for Grafix (p<0.05).
FibroBiologics to present MS data at ACTRIMS; phase 0/1 shows safety, no adverse events
Phase 0/1 safety trial of allogeneic HDFs in 5 MS patients: no adverse events, strong CBC/blood chemistry/ECG correlation.
On July 2, 2026, Matt Link notified FibroBiologics, Inc. (the “Company”) that he was resigning from the Board of Directors (the “Board”), effective as of July 2, 2026.
On July 8, 2026, the Board appointed Kathleen Rubins, Ph.D. as a Class III director of the Board, effective July 8, 2026, to serve until the expiration of her term at the 2029 annual meeting of stockholders.
On June 9, 2025, FibroBiologics, Inc. (the “Company”) announced that Jason D. Davis has been appointed as the Company’s Chief Financial Officer, effective as of June 9, 2025 (the “Effective Date”).
On May 2, 2025, Mr. Robert E. Hoffman informed FibroBiologics, Inc. (the “Company”) of his decision to voluntarily resign from his position as the Company’s Interim Chief Financial Officer, effective as of the close of business on May 14, 2025.
On October 25, 2024, Mr. Mark Andersen informed FibroBiologics, Inc. (the “Company”) of his decision to voluntarily resign from his position as the Company’s Chief Financial Officer
Max materiality 0.90 · Median 0.55 · Most common event other_material